Keytruda Qlex Subcutaneous Version Gets Label Revised After Approval, as Immunotherapy Convenience Enters the Safety-Detail Phase

The move of immune checkpoint inhibitors toward subcutaneous injection changes not only how long patients stay in the clinic, but also how drugs continue to be managed after marketing. Data from the U.S. FDA Drugs@FDA database show that after Keytruda Qlex was approved in 2025, supplemental labeling activity continued in 2026, including BLA 761467/S-007, approved on May 12, which incorporated new safety information into warnings and precautions.

Keytruda Qlex is a fixed combination of pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection. The FDA approved this formulation on September 19, 2025, for the adult and pediatric solid-tumor indications for which intravenous Keytruda has been approved; Merck, meanwhile, said the adult scope covers most Keytruda solid-tumor indications. This difference in wording reflects differences between regulatory announcements and company press releases in how they describe scope, and clinical use must still be based on the official label.

The pivotal study supporting the original approval was MK-3475A-D77, in 377 patients with previously untreated metastatic non-small cell lung cancer, who were assigned in a 2:1 ratio to receive subcutaneous Keytruda Qlex plus chemotherapy or intravenous pembrolizumab plus chemotherapy. FDA data indicated that pembrolizumab exposure was comparable between the two groups; confirmed objective response rates were 45% and 42%, respectively, and no clear differences were observed in progression-free survival or overall survival.

Convenience is the easiest change to understand with a subcutaneous dosage form. According to the FDA label and company materials, the recommended dose can be 395 mg pembrolizumab combined with 4,800 units of berahyaluronidase every 3 weeks, administered in about 1 minute; or 790 mg combined with 9,600 units every 6 weeks, administered in about 2 minutes. Compared with the existing intravenous Keytruda infusion of about 30 minutes, this may have practical implications for outpatient scheduling, infusion-chair use, and patients’ time costs.

But the latest supplemental approval is a reminder that faster administration does not mean the risks of immunotherapy become simpler. The FDA approval letter dated May 12, 2026, shows that the S-007 supplement was received on November 21, 2025, and revised Section 5 of the label, Warnings and Precautions; the new safety labeling includes the addition of myocarditis, myositis, and myasthenia gravis overlap syndrome under “Other Immune-Mediated Adverse Reactions.” The FDA also required updates to structured product labeling and promotional materials to reflect the new safety information.

The May 2026 version of the label also summarized recent major changes: indications and dosage and administration were updated in April, while warnings and precautions were updated in May. The label clearly states that Keytruda Qlex may only be injected subcutaneously into the thigh or abdomen and must not be administered intravenously. Such seemingly technical wording is in fact quite important for healthcare-facility workflows, because when the same active ingredient exists in both intravenous and subcutaneous versions, the administration route, dosage units, and operational training all need to avoid confusion.

Background Context

The focus of this new information is not to re-announce the approval of a blockbuster drug, but to fill in the post-marketing regulatory timeline: Keytruda Qlex has moved from “whether some intravenous administration scenarios can be replaced by a subcutaneous approach” to the stage of “how the label should continue to be calibrated before and after broad use.” Existing public information can explain the approval basis, administration design, and newly added warnings, but it still cannot by itself answer the real-world adoption speed across tumor types, insurance-payment arrangements, or the degree of workflow redesign at different institutions.